A Phase I Study of the Reduced Immunogenicity Mesothelin-Targeted Immunotoxin LMB-100 in Patients With Malignant Mesothelioma

Trial Profile

A Phase I Study of the Reduced Immunogenicity Mesothelin-Targeted Immunotoxin LMB-100 in Patients With Malignant Mesothelioma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs LMB 100 (Primary) ; Paclitaxel
  • Indications Mesothelioma
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Apr 2018 Planned primary completion date changed from 1 Aug 2018 to 6 Aug 2019.
    • 05 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top